Biotech Values

[DewDiligence]

MNTA M118 update from UBS webcast:

In the phase-2a EMINENCE trial in PCI/stable angina, the lowest-dose M118 arm (50 IU/kg) has been dropped. Thus, the trial now consists of three arms: a) M118 at 75 IU/kg; b) M118 at 100IU/kg; and c) the heparin control arm. The total number of patients will now be 500 rather than 600, as originally planned. (Note: these updates are not yet shown in the trial’s listing at clinicaltrials.gov.)

The guidance for reporting data from this trial has also slipped slightly: the prior guidance was “late 1Q09 or early 2Q09”; the new guidance is simply 2Q09.

MNTA still expects to ink a partnership deal for M118 upon completion of the phase-2a trial, i.e. in mid 2009.